Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers

TECHNOLOGY INVESTORS
Gate2Brain

The solution

Gate2Brain
Technology

Gate2Brain (G2B) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

Read more

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Read more
Link to: Technology
Technology

Gate2Brain (G2B) has a proprietary novel technology platform for the delivery of therapeutics across biological barriers.

Follow a manual added link
Pipeline and Therapeutic Proof of Concept

G2B-001, the first therapeutic proof of concept of our technology platform, is aimed mainly at the treatment of rare pediatric solid tumors.

Link to: Investors
Investors

A strong network of investors ensures funding to achieve our goals.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers. We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Therapeutic
Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-001, our flagship product and proof of concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-001 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of oncology, pediatric and rare diseases.

G2B-001 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.

READ MORE
Gate2Brain

News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

De la Ciència al Mercat (From Science to the Marketplace)

Organized by Universitat de Barcelona, Universitat Autònoma de Barcelona, Universitat Politècnica de…
Read more

BStartupHealth DemoDay

Organized by Banc de Sabadell.Gate2Brain participated on January 27 in the BStartupHealth DemoDay…
Read more

Round Table in 100tífiques “Public Research and Research at Large Corporation”

Organized by Barcelona Institut of Science & Technology and Fundació Catalana per a la recerca i…
Read more
Gate2Brain

Gate2Brain co-signs its first article in ACS Publications under the title “Amphiphilic Polymeric Nanoparticles Modified with Protease-Resistant Peptide Shuttle for the Delivery of SN-38 in Diffuse Intrinsic Pontine Glioma”

Alexandra Bukchin, Macarena Sanchez-Navarro, Adam Carrera, Claudia Resa-Pares, Helena Castillo-Ecija,…
Read more
Gate2Brain

BStartup of Banco de Sabadell invests in Gate2Brain biotech

Su tecnología tiene como objetivo transportar fármacos al cerebro aumentando la eficacia y disminuyendo…
Read more
Gate2Brain

Gate2Brain seeks up to 3 million euros to reach the clinical trial

La start up, que desarrolla una tecnología para transportar fármacos al cerebro, utilizará los fondos…
Read more
Gate2Brain

The Mind the Gap program of Botín Foundation invests 1.5 million euros in three new biotech startups

El programa Mind the Gap de la Fundación Botín invierte 1,5 millones de euros en tres nuevas startups…
Read more
Gate2Brain

Launch of Gate2Brain, the “key” to transporting drugs into the brain and improving their effectiveness

Launch of Gate2Brain, the “key” to transporting drugs into the brain and improving their effectiveness…
Read more
NEWS & MEDIA

1
2
Gate2Brain
1

Making therapies a reality for patients by addressing unmet medical needs.

2

Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social